Open Access

Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users

  • Authors:
    • Daisuke Asaoka
    • Tsutomu Takeda
    • Hitoshi Sasaki
    • Yuji Shimada
    • Kenshi Matsumoto
    • Hiroya Ueyama
    • Kohei Matsumoto
    • Kentaro Izumi
    • Hiroyuki Komori
    • Yoichi Akazawa
    • Taro Osada
    • Mariko Hojo
    • Akihito Nagahara
  • View Affiliations

  • Published online on: April 9, 2019     https://doi.org/10.3892/br.2019.1206
  • Pages: 277-282
  • Copyright: © Asaoka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate symptomatic reflux esophagitis (RE) in proton pump inhibitor (PPI) users. The present study conducted a hospital‑based, retrospective cross‑sectional study of consecutive RE cases in PPI users at Juntendo University Hospital recruited between 2008 and 2016. Eligible patients were PPI users with a complete patient profile, who completed the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG) questionnaire, and who underwent upper gastrointestinal endoscopy for the examination of RE, hiatal hernia (HH) and endoscopic gastric mucosal atrophy (EGA). The patients with RE who were administered PPIs were divided into two groups: Those with symptomatic RE (FSSG≥8) and those with non‑symptomatic RE (FSSG<8). The present study investigated the risk factors for symptomatic RE among the patients with RE patients who were administered PPIs. Of the 13,052 cases who underwent patient profiling, the FSSG questionnaire and upper gastrointestinal endoscopy, a total of 2,444 PPI users were eligible. Of the PPI users, 206 cases (8.4%) had RE. Among the 206 patients with RE, 115 (55.8%) had symptomatic RE. The profile of the symptomatic and non‑symptomatic RE groups were as follows: A total of 45 females (39.1%) vs. 32 females (35.2%; non‑significant); mean ± standard deviation age, 54.8±13.5 vs. 62.9±11.1 years (P<0.01); mean body mass index, 23.5±3.3 vs. 23.2±3.8 (non‑significant); severe RE, 12 (10.4%) vs. 2 (2.2%; P<0.05); HH, 70 (60.9%) vs. 40 (44.0%; P<0.05); and mean score of EGA, 1.2±1.8 vs. 1.8±2.1 (P<0.05). Multivariate analysis revealed that a younger age [odds ratio (OR)=0.94; 95% confidence interval (CI): 0.92‑0.97, P<0.01] and HH(+) (OR=2.37; 95% CI: 1.30‑4.34, P<0.01) were associated with symptomatic RE among patients with RE who were administered PPIs. In conclusion, a younger age and HH were associated with symptomatic RE in patients with RE who were administered PPIs.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 10 Issue 5

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Asaoka D, Takeda T, Sasaki H, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, Izumi K, Komori H, Akazawa Y, Akazawa Y, et al: Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users. Biomed Rep 10: 277-282, 2019
APA
Asaoka, D., Takeda, T., Sasaki, H., Shimada, Y., Matsumoto, K., Ueyama, H. ... Nagahara, A. (2019). Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users. Biomedical Reports, 10, 277-282. https://doi.org/10.3892/br.2019.1206
MLA
Asaoka, D., Takeda, T., Sasaki, H., Shimada, Y., Matsumoto, K., Ueyama, H., Matsumoto, K., Izumi, K., Komori, H., Akazawa, Y., Osada, T., Hojo, M., Nagahara, A."Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users". Biomedical Reports 10.5 (2019): 277-282.
Chicago
Asaoka, D., Takeda, T., Sasaki, H., Shimada, Y., Matsumoto, K., Ueyama, H., Matsumoto, K., Izumi, K., Komori, H., Akazawa, Y., Osada, T., Hojo, M., Nagahara, A."Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users". Biomedical Reports 10, no. 5 (2019): 277-282. https://doi.org/10.3892/br.2019.1206